Skip to main content
OpenTrials
Completed

NCT Number: NCT01628588

Lumigan® in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)

This is an observational study of Lumigan® 0.01% (bimatoprost) treatment in clinical practice for patients with Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Glaucoma, Open-Angle Eye Diseases Glaucoma Ocular Hypertension

Sex eligibility

All sexes

Study type

Observational

Primary location

Amsterdam, Netherlands

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis of primary open angle glaucoma or ocular hypertension
  • Prescribed Lumigan®

Exclusion criteria

  • None

Treatment and study plan

Bimatoprost 0.01%

Drug

Patients with POAG or OHT prescribed Lumigan® (bimatoprost 0.01%) treatment in a dose determined by the physician prior to study entry

Primary outcomes

  1. Change From Baseline in Intraocular Pressure (IOP)

    Time frame: Baseline, 14 Weeks

    IOP is a measurement of the fluid pressure inside the eye. A negative change from baseline indicates an improvement.

Secondary outcomes

  1. Patient Assessment of Tolerability Using a 4-Point Scale

    Time frame: 14 Weeks

    Patient assessment of tolerability using a 4-point scale (very good, good, moderate, and poor). The number of patients assessed as good and very good combined are reported.

  2. Physician Assessment of Tolerability Using a 4-Point Scale

    Time frame: 14 Weeks

    Physician assessment of tolerability using a 4-point scale (very good, good, moderate, and poor). The number of patients assessed as good and very good combined are reported.

  3. Patients Who Discontinued Use of Lumigan® Prior to 14 Weeks

    Time frame: 14 Weeks

    Patients who discontinued Lumigan® prior to 14 weeks was assessed as Yes or No.

  4. Patients Who Will Continue Use of Lumigan® After 14 Weeks

    Time frame: 14 Weeks

    Patients who will continue use of Lumigan® after 14 weeks was assessed as Yes or No.

Sponsors and collaborators

Lead sponsor

Allergan

Industry

Registry information

Important dates

Study start
2010
Primary completion
2010
Study completion
2010
First posted
Jun 27, 2012
Registry last updated
Sep 24, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.